KDM4A抗体

+ +

•  

   

     Immunofluorescence analysis of NTERA-2 cells using KDM4A mouse mAb (green). Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human colon cancer tissues (left) and human larynx cancer tissues (right) using KDM4A mouse mAb with DAB staining.    

  
  

The KDM4A antibody is a tool used to detect and study the KDM4A protein, a member of the lysine demethylase 4 (KDM4/JMJD2) family. KDM4A, also known as JMJD2A, is an epigenetic regulator that specifically demethylates histone H3 on lysine 9 (H3K9me3/me2) and lysine 36 (H3K36me3/me2), modulating chromatin structure and gene expression. It plays critical roles in transcriptional regulation, DNA replication, repair, and cellular differentiation. Dysregulation of KDM4A is linked to cancers, metabolic disorders, and developmental defects due to its impact on oncogene activation, genome stability, and cell proliferation pathways.

The KDM4A antibody is widely utilized in research to assess protein expression, localization, and function via techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP). Researchers employ it to investigate KDM4A's role in tumorigenesis, stem cell biology, and response to therapeutic agents. For instance, its overexpression in certain cancers (e.g., breast, prostate) has made it a potential biomarker or therapeutic target. The antibody's specificity is validated using knockout controls or peptide blocking to ensure accurate detection. Commercial variants may differ in clonality, epitope recognition, or conjugation, requiring optimization for experimental conditions. Understanding KDM4A's mechanisms through such antibodies contributes to advancing epigenetic therapies and precision medicine.